AzTrials
AzTrials

Aortic AneurysmNCT02471781

Zenith® TX2® Low Profile TAA Endovascular Graft

A study testing Zenith TX2 Low Profile TAA Endovascular Graft in people with Aortic Aneurysm and Penetrating Ulcer, run by Cook Group Incorporated at 15 sites in United States.

Approved For Marketing

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The Zenith TX2 Low Profile TAA Endovascular Graft extended study is to collect confirmatory safety and effectiveness data. The Zenith TX2 Low Profile TAA Endovascular Graft is indicated for the treatment of patients with a descending thoracic aortic aneurysm or penetrating ulcer and has an anatomy suitable for repair. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Zenith TX2 Low Profile TAA Endovascular Graft
Type of treatment
Medical device
How many people
Not given
Where
15 sitesUnited States
Study dates
Start not givento not given
Phase
Expanded access
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Meets one of the following
  • Descending thoracic aneurysm with diameter ≥ 5.0 cm
  • Descending thoracic aneurysm with a history of growth ≥ 0.5 cm per year
  • Descending thoracic degenerative or atherosclerotic ulcer ≥ 10 mm in depth and 20 mm in diameter

Who cannot join

  • Life expectancy less than 2 years
  • Pregnant of breastfeeding or planning on becoming pregnant within 60 months
  • Unwilling to comply with the follow-up schedule
  • Less than 30 days beyond primary endpoint for other investigative drug or device study
  • Receiving home oxygen
  • Myocardial infarction within the last 3 months
Show all 13Show fewer
  • Stroke within the last 3 months
  • Diagnosed or suspected congenital degenerative collagen disease
  • Systemic infection
  • Bleeding diathesis, uncorrectable coagulopathy, or refuses blood transfusion
  • Allergy to polyester, polypropylene, nitinol, or gold
  • Previous placement of a thoracic endovascular graft
  • Prior open repair involving the descending thoracic aorta

Trial locations and contacts

15 sites in 1 country.

15 sites in 1 country

United States15 sites
  • University of Michigan Health System

    Ann Arbor, Michigan, 48109

  • Emory University

    Atlanta, Georgia, 30322

  • Cooper University Hospital

    Camden, New Jersey, 08103

  • University of North Carolina

    Chapel Hill, North Carolina, 27599

  • Ohio State University

    Columbus, Ohio, 43210

  • Duke University Medical Center

    Durham, North Carolina, 27710

  • Hackensack University Medical Center

    Hackensack, New Jersey, 07601

  • Methodist Hospital of Indiana

    Indianapolis, Indiana, 46202

  • Indiana Heart Hospital

    Indianapolis, Indiana, 46250

  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshire, 03756

  • The Mount Sinai Hospital

    New York, New York, 10029

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania, 19104

  • Mayo Clinic

    Rochester, Minnesota, 55905

  • Barnes-Jewish Hospital

    St Louis, Missouri, 63110

  • University of South Florida

    Tampa, Florida, 33606

Other trials in United States

About this study

Official title: Zenith® TX2® Low Profile TAA Endovascular Graft Clinical Study

The Zenith TX2 Low Profile TAA Endovascular Graft extended study is to collect confirmatory safety and effectiveness data. The Zenith TX2 Low Profile TAA Endovascular Graft is indicated for the treatment of patients with a descending thoracic aortic aneurysm or penetrating ulcer and has an anatomy suitable for repair.

Being tested
Zenith TX2 Low Profile TAA Endovascular Graft
Keywords
Aortic Aneurysm, Aneurysm, Vascular Prosthesis, Vascular Disease, Blood Vessel Prosthesis Implantation
Medical subject headings
Aortic Aneurysm, Penetrating Atherosclerotic Ulcer, Vascular Diseases, Aneurysm

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Zenith TX2 Low Profile TAA Endovascular GraftDevice

    Also called Zenith Alpha Thoracic™ Endovascular Graft

    Endovascular treatment of patients with aneurysms or ulcers of the descending thoracic aorta having morphology suitable for endovascular repair.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Jun 2015 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Expanded access
IDs, dates and publications
ClinicalTrials.gov ID
NCT02471781
Sponsor's protocol ID
10-001 CA
Status last verified
Jan 2020
First submitted
11 Jun 2015
Last updated
18 Jan 2020
Results posted
No

Questions about this trial

What is this clinical trial studying?

A study testing Zenith TX2 Low Profile TAA Endovascular Graft in people with Aortic Aneurysm and Penetrating Ulcer, run by Cook Group Incorporated at 15 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 18 Jan 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 15 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jan 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in